Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety

• Published in: Journal of pharmacology & pharmacotherapeutics 2011-07, Vol.2 (3), p.150-157
• Main Authors: Maiti, Rituparna, Jaida, Jyothirmai, Israel, P L John, Koyagura, Narendar, Mukkisa, Sruthi, Palani, Anuradha
• Format: Article
• Language: English
• Subjects: Dosage and administration; Drug therapy; Dysphagia; Gastroesophageal reflux; Inflammatory bowel disease; Pharmaceutical industry; Quality of life; Rabeprazole; Research Paper; Throat
• ISSN: 0976-500X; 0976-5018
• DOI: 10.4103/0976-500X.83278

To compare the efficacy and safety of rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease (GERD). A randomized, single-blinded, outdoor-based clinical study was conducted on 60 patients of mild-to-moderate erosive GERD. After baseline clinical assessment and investigations, rabeprazole (40 mg) was prescribed to 30 patients and esomeprazole (40 mg) to another 30 patients for 4 weeks. The efficacy variables were change in GERD symptom scoring, endoscopic findings, and Quality of Life in Reflux and Dyspepsia (QOLRAD) scoring over 4 weeks. Heartburn, acid regurgitation, and overall GERD symptom scoring (P = 0.01) were significantly decreased with rabeprazole in comparison to esomeprazole. The comparative study of all five domains of the QOLARD questionnaire including overall scoring revealed a statistically significant improvement in the rabeprazole group. Endoscopic findings in the rabeprazole group showed an absolute improvement of 30% and relative improvement of 55% over esomeprazole. Both the drugs were well tolerated having no significant difference in the incidence of adverse effects. Rabeprazole (40 mg) is a better choice for mild-to-moderate GERD compared with esomeprazole (40 mg) because of its better efficacy and safety profile.